Antibodies to watch in 2025
Tuesday 4 February 2025
07:00 [PST] 10:00 [EST] 15:00 [GMT]
In this webinar, brought to you by The Antibody Society (MA, USA), in association with the journal mAbs, Drs. Crescioli and Reichert discuss the recent trends in antibody therapeutics development presented in the annual mAbs publication detailing the ‘antibodies to watch’ for the upcoming year. They briefly review approvals from 2024 and product candidates with recent marketing applications under consideration, providing insight into the factors influencing the emerging trends in this field, before exploring the investigational antibody therapeutics forecast to enter regulatory review by the end of 2025. These product candidates include numerous innovative bispecific antibodies and antibody-drug conjugates.
They also discuss clinical phase transition and overall approval success rates for antibody therapeutics, which are crucial to the biopharmaceutical industry. Overall, the data suggest that the industry’s antibody therapeutics development efforts are robust and increasingly successful.
What will you learn?
- Trends in antibody therapeutics development
- Clinical phase and approval success rates for unconventional antibody formats such as bispecifics and ADCs
- Projections for antibody therapeutics approvals in 2025 and 2026
The annual “Antibodies to Watch” articles published in mAbs from 2010 to 2024 can be found here.
Who this may interest?
- Antibody enthusiasts
- Research scientists
- Strategic intelligence experts
- Portfolio managers
Speaker
Silvia Crescioli
Business Intelligence Creator
The Antibody Society, Inc.
Dr. Silvia Crescioli is a Consultant for The Antibody Society. Since 2021 she has co-authored the “Antibodies to watch” articles in published in mAbs. Dr. Crescioli received her PhD in Biomedical Sciences, Experimental Oncology, from the University of Florence in 2014, then held a post doc position at King’s College London in Prof. Karagiannis’ Cancer Antibody Discovery & Immunotherapy Group, where she is now a visiting Research Fellow. Her research interests focus on antibody therapeutics development for both cancer and noncancer indications, as well as on different areas of cancer immunology and immunotherapy, including antibody discovery, antibody engineering and glycoengineering.
Janice Reichert
Director of Business Intelligence
The Antibody Society, Inc.
Dr. Janice Reichert, Director of Business Intelligence at The Antibody Society, is an internationally recognized expert in the development of antibody therapeutics. She is Founder and Editor-in-Chief of mAbs, a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development. Dr. Reichert has published extensively on development trends for antibody therapeutics, and she has presented her research results as an invited speaker at conferences held worldwide. Dr. Reichert received her PhD in Chemistry from the University of Pennsylvania and did her post-doctoral training at Harvard Medical School.
In association with
and
